These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10217347)

  • 1. Urine fingerprinting: detection of sample tampering in an opiate dependency program.
    Kapur B; Hershkop S; Koren G; Gaughan V
    Ther Drug Monit; 1999 Apr; 21(2):243-50. PubMed ID: 10217347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing.
    Huestis MA; Cone EJ; Wong CJ; Umbricht A; Preston KL
    J Anal Toxicol; 2000 Oct; 24(7):509-21. PubMed ID: 11043653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine drug screening: a valuable office procedure.
    Standridge JB; Adams SM; Zotos AP
    Am Fam Physician; 2010 Mar; 81(5):635-40. PubMed ID: 20187600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance with methadone-based substitutive treatment: a proposed model based on immunoassay urinary sample screening.
    Bézie Y; Talon V; Lillo A; Illier C; Billaud E; Prognon P; Boutouyrie P
    Ther Drug Monit; 2004 Jun; 26(3):271-6. PubMed ID: 15167627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Papain: a novel urine adulterant.
    Burrows DL; Nicolaides A; Rice PJ; Dufforc M; Johnson DA; Ferslew KE
    J Anal Toxicol; 2005; 29(5):275-95. PubMed ID: 16105251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
    Heikman P; Sundström M; Pelander A; Ojanperä I
    Hum Psychopharmacol; 2016 Jan; 31(1):44-52. PubMed ID: 26763789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opiate DAU screening using dried urine specimens.
    Meany DL; Clarke W
    Clin Chim Acta; 2009 Mar; 401(1-2):188-9. PubMed ID: 19068209
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results.
    Bertholf RL; Johannsen LM; Reisfield GM
    J Anal Toxicol; 2015; 39(1):24-8. PubMed ID: 25288720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid Use Disorders, Medication-Assisted Treatment, and the Role of the Laboratory.
    Bertholf RL; Reisfield GM
    Lab Med; 2017 Nov; 48(4):e57-e61. PubMed ID: 29096016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disaccharides in urine samples as markers of intravenous abuse of methadone and buprenorphine.
    Jungen H; Andresen-Streichert H; Müller A; Iwersen-Bergmann S
    J Anal Toxicol; 2013; 37(9):652-8. PubMed ID: 24099717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of drug testing using exhaled breath for compliance monitoring of drug addicts in treatment.
    Carlsson S; Olsson R; Lindkvist I; Beck O
    Scand J Clin Lab Invest; 2015 Apr; 75(2):156-61. PubMed ID: 25562730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An investigation of normal urine with a creatinine concentration under the cutoff of 20 mg/dL for specimen validity testing in a toxicology laboratory.
    Holden B; Guice EA
    J Forensic Sci; 2014 May; 59(3):806-10. PubMed ID: 24502684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a polyethylene glycol marker system in urine drug screening in an opiate substitution program.
    Schneider HJ; Rühl B; Meyer K; Keller R; Backmund M
    Eur Addict Res; 2008; 14(4):186-9. PubMed ID: 18583915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine Creatinine Concentrations in Drug Monitoring Participants and Hospitalized Patients.
    Love SA; Seegmiller JC; Kloss J; Apple FS
    J Anal Toxicol; 2016 Oct; 40(8):659-662. PubMed ID: 27590035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic investigations of novel validity parameters in urine drug testing and prevalence of urine adulteration in a two-year cohort.
    Kluge J; Rentzsch L; Remane D; Peters FT; Wissenbach DK
    Drug Test Anal; 2018 Oct; 10(10):1536-1542. PubMed ID: 29956490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct analysis of opiates in urine by liquid chromatography-tandem mass spectrometry.
    Edinboro LE; Backer RC; Poklis A
    J Anal Toxicol; 2005 Oct; 29(7):704-10. PubMed ID: 16419404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of oral fluid in compliance monitoring of opioid medications.
    Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
    Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine pH: the effects of time and temperature after collection.
    Cook JD; Strauss KA; Caplan YH; Lodico CP; Bush DM
    J Anal Toxicol; 2007 Oct; 31(8):486-96. PubMed ID: 17988463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring Intravenous Abuse of Methadone or Buprenorphine in Opiate Maintenance Treatment (OMT): A Simple and Fast LC-MS-MS Method for the Detection of Disaccharides in Urine Samples.
    Jungen H; Andresen-Streichert H; Müller A; Iwersen-Bergmann S
    J Anal Toxicol; 2017 Jan; 41(1):22-31. PubMed ID: 28130543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.